
HPMC Capsule Offers Simpler Formulation
Key Takeaways
- Quali-V Pure uses only HPMC and water, removing carrageenan-like gelling agents to simplify excipient declarations and potentially ease formulation and regulatory considerations.
- Consistent dissolution across varied pH environments is a central performance claim, addressing variability concerns seen with some capsule systems under differing GI conditions.
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
At CPHI Milan 2026 in October, Roquette previewed Quali-V Pure, a hydroxypropyl methylcellulose (HPMC) capsule made from just HPMC and water, with no gelling agents such as carrageenan. The company says the simpler formula meets formulators’ growing demand for shorter excipient lists, for both formulation and regulatory reasons. Roquette also says the capsule dissolves consistently across pH conditions and has a low moisture content suited to moisture-sensitive formulations. In this interview, Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions business, discusses the capsule ahead of its 2027 commercial launch, the patient-centric pressures reshaping drug delivery, and her highlights from this year’s show.
PharmTech: What should manufacturers expect in terms of performance versus existing HPMC or gelatin options?
Bergerone:To clarify one point first: Quali-V Pure is an HPMC capsule made without gelling agents such as carrageenan, and that is precisely what sets it apart. We are hearing a clear demand from formulators for simpler, shorter excipient compositions, both for formulation and regulatory reasons. Quali-V Pure answers that with just HPMC and water. In terms of performance, Quali-V Pure is designed to deliver a consistent dissolution behavior under different pH conditions. Its plant-based HPMC composition offers an alternative to animal-derived gelatin, while its low moisture content makes it particularly attractive for moisture-sensitive and hygroscopic formulations.
As formulation requirements continue to evolve and customers look for solutions that give them more choices while maintaining the quality and consistency they expect from a trusted partner, we were pleased to introduce Quali-V Pure at CPHI 2026. Quali-V Pure is the next evolution of our HPMC capsule platform, complementing our established portfolio.
With Quali-V Pure, we wanted to build on the trusted Quali-V HPMC capsule portfolio and offer our customers an additional option designed around simplicity. Quali-V Pure has a deliberately simple composition—HPMC and water—with no gelling agents. By removing the need for those agents, we are offering an alternative for those who want a more straightforward HPMC capsule formulation. We are looking forward to our commercial launch in 2027.
What specific industry or patient needs are pushing pharma innovators to rethink their drug delivery approaches?
Pharmaceutical innovation is increasingly being shaped by the need to balance technical performance with patient experience. Developers must consider not only whether a product delivers its intended function, but also how easily and comfortably patients can take it, and whether the dosage form meets the needs of the people using it. All of these are fundamental to adherence and achieving positive outcomes.
Meeting these expectations requires more than selecting the right active ingredient. Formulators must navigate a complex set of challenges, including manufacturability, stability, regulatory requirements, and patient acceptability, while maintaining product performance throughout development and commercialization. As healthcare continues to move toward more patient-centric solutions, dosage forms that are convenient, accessible, and easy to administer are becoming increasingly important differentiators.
Successfully translating these goals into commercially viable products demands both formulation expertise and a deep understanding of how excipients and processing technologies influence the final dosage form. Early consideration of potential technical hurdles can help developers streamline development, reduce risk, and accelerate the path from concept to market.
At Roquette, we believe the answer lies in combining high-quality ingredients with formulation expertise and close collaboration with customers. By understanding the challenges they face early in development, we can help them manage technical risks, navigate regulatory requirements, and bring solutions to market faster, and with greater confidence.
What did you enjoy most about CPHI Milan this year, and what was the highlight for you?
I enjoyed the opportunity to reconnect with customers and industry partners, exchange perspectives, and hear directly about the challenges they are working to solve. It’s really about the opportunity to have quality conversations where we can look beyond individual products and understand the bigger picture.Our discussions provided insight and understanding into how our customers’ needs are evolving, what formulation challenges exist, and how we can work together to make a meaningful difference.
More broadly, I enjoyed seeing the level of innovation across the industry and the willingness of partners to collaborate on increasingly complex challenges. A real highlight was the response to the Quali-V Pure preview—the conversations at our booth confirmed that customers are looking for exactly this kind of simplicity.
About the Speaker
Chiara Bergerone was appointed Deputy CEO of Roquette’s Health and Pharma Solutions Business Unit in 2026. Her career began in specialty chemicals, leading complex industrial projects across Europe and the US. She then moved into healthcare and MedTech, where she progressed into general management roles with full responsibility for commercial performance and innovation, building high-performing teams and launching innovative solutions for better patient care. Today, she leads the commercial, strategic marketing, product line management, and business development organizations for Health and Pharma Solutions, driving the business unit’s growth strategy and its mission to deliver differentiated pharmaceutical solutions for patients worldwide. Chiara holds a degree in Biomedical Materials Engineering from Politecnico di Torino, a degree in Physics from Grenoble INP, and an MBA from the Collège des Ingénieurs (CDI) in Paris.
Related to this article








